RTX-GRT7039 Injections for Knee Osteoarthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial uses knee injections called RTX-GRT7039 for patients with knee osteoarthritis who still have pain despite usual treatments. The injections aim to reduce knee pain, possibly by affecting pain pathways or inflammation.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
How is the treatment RTX-GRT7039 different from other treatments for knee osteoarthritis?
RTX-GRT7039 is unique because it is a specific injection treatment for knee osteoarthritis, which may involve a novel mechanism or formulation not covered by existing studies on regenerative injection therapy, triamcinolone hexacetonide, hyaluronic acid, or platelet-rich plasma injections. However, the exact details of how RTX-GRT7039 works or its specific benefits compared to these treatments are not provided in the available research.12345
What data supports the effectiveness of the treatment RTX-GRT7039 for knee osteoarthritis?
Are You a Good Fit for This Trial?
This trial is for adults over 18 with knee osteoarthritis who haven't found pain relief from standard treatments. They must be able to consent to the study and have a functional capacity class of I to III, based on specific medical criteria.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive intra-articular injections of RTX-GRT7039 into the affected knee(s)
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- RTX-GRT7039
Find a Clinic Near You
Who Is Running the Clinical Trial?
Grünenthal GmbH
Lead Sponsor
Gabriel Baertschi
Grünenthal GmbH
Chief Executive Officer since 2016
Biology degree from the University of Neuchâtel
Prof. Dr. Uli Brödl
Grünenthal GmbH
Chief Medical Officer
MD from Ludwig-Maximilians University Munich